Equine Herpesvirus Myeloencephalopathy (EHM)

Equine Herpesvirus Myeloencephalopathy represents the neurological manifestation of Equine Herpesvirus-1 infection, causing devastating inflammation of the spinal cord and brain blood vessels that can result in sudden paralysis, recumbency, and death. This severe complication of EHV-1 infection occurs when the virus damages blood vessels supplying the central nervous system, leading to ischemic injury of neural tissue. EHM has emerged as a significant concern in the equine industry, causing sporadic cases and devastating outbreaks at competitions, breeding farms, and veterinary hospitals that can affect multiple horses and require extensive quarantine measures.

Equine Herpesvirus Myeloencephalopathy can affect horses of any breed, age, or use, though certain factors influence susceptibility to the neurological form of infection. While EHV-1 infection is extremely common in horse populations worldwide, with most horses experiencing respiratory infection during their lifetime, only a small percentage develop neurological disease. The factors determining which infected horses develop EHM remain incompletely understood, though viral strain characteristics, particularly a specific mutation associated with increased neurotropism, play a significant role.

The impact of EHM on equine health extends beyond individual affected horses to affect entire facilities and the broader horse community through quarantine requirements and event cancellations. Outbreaks have forced suspension of horse shows, racing meets, and sales, causing significant economic disruption. The highly contagious nature of EHV-1, combined with the unpredictable development of neurological disease, creates anxiety whenever outbreaks occur. Horses that survive EHM often retain permanent neurological deficits, while severely affected horses may require euthanasia due to inability to stand.

Early detection and aggressive supportive treatment offer the best chance for survival and recovery from Equine Herpesvirus Myeloencephalopathy. Recognizing the initial signs of EHV-1 infection, particularly fever, allows implementation of isolation protocols that limit viral spread while monitoring for neurological complications. Understanding this condition enables horse owners, farm managers, and veterinarians to implement biosecurity measures that reduce outbreak risk and respond effectively when cases occur.

The primary cause of Equine Herpesvirus Myeloencephalopathy is infection with Equine Herpesvirus-1, a highly prevalent pathogen that causes respiratory disease, abortion, and neurological disease in horses. While EHV-1 infection is common, neurological disease develops in only a subset of infected horses through a process involving viral-induced damage to blood vessels in the central nervous system. The virus spreads through the bloodstream during viremia and infects endothelial cells lining blood vessels in the brain and spinal cord, causing vasculitis that restricts blood flow and produces ischemic damage to neural tissue.

Genetic factors influence susceptibility to EHM at both the viral and host levels. Certain strains of EHV-1, particularly those carrying a specific mutation in the DNA polymerase gene, demonstrate enhanced ability to cause neurological disease compared to wild-type strains. This neuropathogenic mutation affects viral replication characteristics that influence viremia levels and endothelial cell infection. Host factors also influence susceptibility, with individual variations in immune response affecting the likelihood of developing neurological complications following infection.

Environmental and management factors significantly influence EHV-1 transmission and outbreak risk. Crowded conditions at shows, sales, and training facilities facilitate viral spread between horses. Stress from transportation, competition, and changes in social groups can reactivate latent EHV-1 infections and increase viral shedding. Inadequate biosecurity practices allow rapid spread through populations. Commingling of horses from diverse sources at events creates opportunities for introduction of novel viral strains to susceptible populations.

Risk factors for developing EHM include older age, with horses over twenty years showing increased susceptibility to neurological complications. Horses experiencing significant stress, those with compromised immune function, and pregnant mares face elevated risk. Exposure to neuropathogenic viral strains increases likelihood of neurological disease. Prior EHV-1 infection does not provide complete protection and may not prevent development of neurological disease during subsequent infections. Horses that have recovered from EHM are not immune to future episodes.

The pathophysiology of EHM involves viral infection of vascular endothelial cells in the central nervous system, triggering inflammation and vasculitis that restricts blood flow to neural tissue. The resulting ischemia causes hypoxic damage to neurons in affected areas, particularly the spinal cord. The distribution of vascular damage determines clinical presentation, with spinal cord involvement producing the characteristic hindlimb weakness and paralysis. Thrombosis of small vessels compounds ischemic injury. Secondary inflammation contributes to ongoing tissue damage even as the viral infection resolves.

Early warning signs of Equine Herpesvirus Myeloencephalopathy often begin with nonspecific signs of EHV-1 respiratory infection before neurological symptoms develop. Fever typically appears first, with temperatures often exceeding 102 to 104 degrees Fahrenheit, sometimes occurring several days before neurological signs. Depression, decreased appetite, and mild respiratory signs including nasal discharge may accompany fever. Limb edema affecting the lower legs develops in some horses. These early signs are easily attributed to routine respiratory infection, making recognition of impending neurological disease challenging.

Common symptoms of EHM reflect damage to the spinal cord and characteristically affect the hindquarters more severely than the front end. Hindlimb weakness ranging from subtle incoordination to complete paralysis develops rapidly over hours to days. Affected horses may appear to have a weak or wobbly hindquarters while the front end remains relatively strong. Urinary incontinence and inability to control urination results from spinal cord dysfunction affecting bladder control. Fecal retention may occur as bowel function is similarly affected. Loss of tail tone is common and easily assessed.

Behavioral changes in horses developing EHM may include unusual quietness, reluctance to move, or apparent anxiety as they sense their deteriorating coordination. Horses may stand with their hindlimbs placed abnormally wide or may lean against walls for support. Some horses become agitated when asked to move, recognizing their impaired ability. Depression beyond that expected from simple respiratory infection may indicate developing neurological involvement.

Physical signs of EHM include diminished proprioception in the hindlimbs, tested by manually placing feet in abnormal positions and assessing the horse's response. Knuckling of the rear fetlocks may occur as weakness progresses. The tail often hangs limply and provides no resistance when pulled aside. In males, penile paralysis may cause the penis to remain extended. Reduced anal tone is detectable on rectal examination. Skin sensation may be diminished over the hindquarters in some cases.

Symptom progression in EHM typically occurs rapidly, with horses potentially deteriorating from initial neurological signs to recumbency within twenty-four to forty-eight hours. The speed of progression often predicts outcome, with rapidly deteriorating horses facing poorer prognosis than those who stabilize with moderate deficits. Some horses develop a characteristic dog-sitting posture where the front end remains standing while the hindquarters collapse. Once recumbent, many horses are unable to rise despite assistance.

Emergency symptoms requiring immediate veterinary attention include any hindlimb weakness or incoordination in horses with fever or known EHV-1 exposure. Inability to stand, recumbency, or dog-sitting posture constitute emergencies requiring immediate intervention. Urinary retention with inability to urinate normally indicates severe spinal cord dysfunction. Rapid progression of any neurological signs warrants emergency response. Given the contagious nature of EHV-1, veterinary notification should occur at the first sign of fever to implement isolation before neurological disease develops.

Physical examination for suspected Equine Herpesvirus Myeloencephalopathy includes thorough neurological evaluation combined with assessment for signs of systemic EHV-1 infection. Temperature measurement often reveals fever, particularly early in disease course. Respiratory examination may show nasal discharge and mild signs of upper respiratory infection. Neurological examination characterizes the distribution and severity of deficits, typically revealing hindlimb involvement exceeding forelimb deficits. Assessment of urinary and fecal function evaluates autonomic involvement. The presence of limb edema, characteristic of EHV-1 infection, supports diagnosis.

Diagnostic tests for EHM focus on confirming EHV-1 infection and characterizing the specific viral strain involved. Nasal swab samples submitted for PCR testing detect viral DNA and confirm active infection. Blood samples may detect viremia during the acute phase. Serological testing comparing acute and convalescent antibody titers can confirm recent infection. Cerebrospinal fluid analysis may show increased protein levels and evidence of inflammation, though changes are variable. PCR testing of cerebrospinal fluid occasionally detects viral presence in the central nervous system.

Advanced diagnostics help exclude other causes of neurological disease and assess spinal cord status. Cervical radiographs and myelography rule out cervical vertebral malformation as a cause of spinal ataxia. MRI, when available, may demonstrate spinal cord abnormalities consistent with ischemic injury and edema. Testing for other causes of infectious neurological disease, including Equine Protozoal Myeloencephalitis and West Nile Virus, helps establish the correct diagnosis. Genetic testing of viral isolates can identify the neuropathogenic mutation associated with increased EHM risk.

Differential diagnosis for acute onset hindlimb paresis includes spinal cord trauma from injury, equine protozoal myeloencephalitis presenting with posterior involvement, West Nile Virus infection causing similar neurological signs, cervical vertebral malformation, and spinal cord neoplasia. The combination of fever, respiratory signs, and hindlimb predominant neurological disease strongly suggests EHM when EHV-1 is confirmed. Outbreak situations with multiple affected horses provide epidemiological support for diagnosis.

Emergency and immediate treatment for Equine Herpesvirus Myeloencephalopathy focuses on reducing inflammation, supporting spinal cord function, and preventing secondary complications. Intravenous corticosteroids, typically dexamethasone, reduce inflammation and edema affecting the spinal cord. Anti-inflammatory medications including flunixin meglumine provide additional inflammatory control and comfort. Intravenous fluid therapy maintains hydration and supports cardiovascular function. DMSO administration may provide additional anti-inflammatory and free radical scavenging effects. Strict isolation protocols prevent transmission to other horses while treatment proceeds.

Medical management of EHM continues beyond initial emergency treatment with ongoing anti-inflammatory therapy and supportive care. Antiviral medications, particularly valacyclovir, may be administered though efficacy remains uncertain once neurological signs develop. Anticoagulant therapy using aspirin or other agents may help prevent ongoing thrombosis in affected blood vessels. Management of urinary function includes bladder catheterization if retention develops. Fecal management addresses constipation or impaction. Nutritional support ensures adequate intake during illness.

Surgical options do not exist for treating the neurological damage of EHM, as the injury results from vascular inflammation and ischemia rather than mechanically correctable lesions. Management remains entirely medical and supportive. In horses requiring long-term bladder management, indwelling catheterization may be necessary. Treatment focuses on maximizing the body's healing capacity while preventing complications that could worsen outcome.

Supportive care for recumbent horses with EHM is intensive and requires continuous monitoring. Frequent repositioning, typically every two to four hours, prevents pressure sores and supports blood flow to dependent tissues. Deep, soft bedding protects against skin breakdown. Sling systems may support partially ambulatory horses though are less useful for completely paralyzed individuals. Eye protection prevents corneal damage in recumbent horses. Padding of bony prominences reduces trauma risk.

Rehabilitation and return to function depends entirely on the extent of permanent neurological damage following the acute disease phase. Horses that remain standing throughout illness and show improvement within the first week have better chances for meaningful recovery. Physical therapy programs help maintain muscle mass and support return of function. Hydrotherapy may benefit recovering horses. Progressive exercise programs advance as neurological function improves. Many survivors retain some permanent deficits affecting their level of use.

Treatment decision factors in EHM include the severity and rate of neurological deterioration, whether the horse remains standing or has become recumbent, response to initial treatment, and available resources for intensive care. Horses that become recumbent face very poor prognosis, with most requiring euthanasia due to complications of recumbency or failure to recover standing ability. Early aggressive treatment in horses with mild to moderate deficits offers better chances for survival. The emotional and financial demands of treating severe cases warrant honest discussion of prognosis before undertaking intensive care efforts.

Recovery timeline for horses surviving Equine Herpesvirus Myeloencephalopathy varies dramatically based on initial severity and response to treatment. Horses with mild neurological involvement may show improvement within days and recover substantially within weeks. Moderate cases typically require months of recovery time with gradual improvement in function. Severely affected horses that survive require prolonged rehabilitation over many months and frequently retain permanent deficits. Maximum improvement may not be achieved for six months to a year following acute illness.

Post-treatment care and monitoring for EHM survivors continues long after the acute illness resolves. Regular neurological assessment tracks ongoing recovery and identifies any complications. Management of residual urinary dysfunction, if present, prevents secondary bladder infection and kidney damage. Ongoing physiotherapy supports muscle maintenance and functional improvement. Nutritional management ensures adequate support for healing while maintaining appropriate body condition. Monitoring for complications including laminitis, particularly in horses with limited mobility, remains important.

Prognosis factors strongly influencing recovery outcomes include whether the horse remained standing throughout acute illness, the speed of deterioration and response to treatment, the severity of neurological deficits at their worst, and age and overall health status. Horses that never become recumbent have substantially better prognosis than those that go down. Rapid response to treatment within the first forty-eight to seventy-two hours suggests better outcome. Younger, otherwise healthy horses may recover more completely than older or compromised individuals.

Long-term soundness outlook for EHM survivors ranges from complete functional recovery to permanent significant disability. Some horses recover fully and return to previous athletic use with no apparent residual effects. Others retain mild deficits that limit high-level athletic performance but allow modified use. A proportion of survivors have moderate deficits compatible with light riding or companion use. Severely affected survivors may have permanent significant deficits requiring ongoing management considerations. Quality of life assessment helps determine appropriate expectations for individual horses.

Management practices to prevent Equine Herpesvirus Myeloencephalopathy center on biosecurity measures that limit EHV-1 transmission between horses. Isolation of new arrivals for two to three weeks before introduction to resident populations allows observation for developing illness. Monitoring temperatures of all horses daily during risk periods enables early detection of fever that precedes viral shedding. Limiting commingling of horses from different sources at events reduces transmission opportunities. Using dedicated equipment for each horse and practicing good hand hygiene between horses limits indirect transmission.

Nutritional prevention strategies do not directly prevent EHV-1 infection or EHM, though supporting overall health and immune function through optimal nutrition may influence disease outcomes. Adequate vitamin E and selenium support immune function. Maintaining horses in good body condition provides nutritional reserves during illness. Minimizing other stressors, including nutritional stress, may reduce susceptibility to viral reactivation and disease progression.

Exercise and conditioning do not directly prevent EHM, but management of training and competition schedules can reduce risk factors for disease development. Avoiding excessive stress from intensive competition or training schedules supports immune function. Allowing adequate recovery between competitions reduces cumulative stress. Being aware of EHV-1 activity in the competition circuit and adjusting schedules accordingly provides practical protection.

Environmental factors influencing EHM prevention include facility design and management practices that support biosecurity. Adequate ventilation in barns reduces aerosol transmission. Appropriate stocking density limits close contact between horses. Isolation facilities allow separation of new arrivals and sick horses. Manure management and sanitation protocols reduce environmental viral persistence. Vector control may have limited relevance as EHV-1 spreads primarily through direct contact and respiratory secretions.

Vaccination protocols for EHV-1 provide incomplete protection, as current vaccines do not reliably prevent neurological disease even when they reduce respiratory disease and abortion risk. However, vaccination may reduce viral shedding and help limit outbreak spread. Modified live and inactivated vaccines are available, with recommendations typically including vaccination of pregnant mares and horses at high risk due to frequent travel or competition. Vaccination should not replace biosecurity measures and should be viewed as one component of a comprehensive prevention program.

Daily management adjustments for horses recovering from Equine Herpesvirus Myeloencephalopathy accommodate residual neurological deficits while supporting continued recovery. Housing should provide secure footing and adequate space for horses with coordination challenges. Monitoring frequency may need to increase during periods of increased fall risk. Assistance with feeding and watering may be needed for horses with significant deficits. Ongoing bladder management continues if urinary function remains impaired. Daily neurological assessment tracks recovery progress.

Housing and turnout considerations for EHM survivors balance rehabilitation benefits of movement against fall risk from residual deficits. Small paddocks with secure footing allow supervised turnout for horses capable of safe independent movement. Gradual expansion of turnout area occurs as function improves. Companion selection avoids horses that might challenge or injure recovering individuals. Weather conditions affecting footing may require modified turnout schedules. Indoor housing may be necessary during recovery phases when outdoor conditions are unsafe.

Exercise modifications during recovery from EHM progress gradually as neurological function improves. Initial exercise may be limited to careful hand walking on level, secure surfaces. Progression to larger areas occurs as coordination improves. Swimming or underwater treadmill work may provide exercise while reducing fall risk. Return to ridden work, if appropriate, proceeds very gradually with careful attention to balance and coordination. Some horses may never return to ridden work depending on residual deficits.

Monitoring and ongoing care for EHM survivors includes regular veterinary assessment to track recovery and identify any complications. Hoof care continues on appropriate schedules, with modifications for horses that cannot be worked normally. Dental care ensures adequate nutrition intake. Monitoring for secondary issues including muscle atrophy from disuse, laminitis in horses with limited mobility, and urinary tract infections in horses with bladder dysfunction guides preventive and corrective interventions.

Quality of life considerations for horses with permanent deficits from EHM require honest assessment of comfort, safety, and ability to engage in normal equine behaviors. Horses with mild residual deficits often maintain excellent quality of life with appropriate management and may return to modified use. Moderate deficits require evaluation of whether acceptable quality of life can be maintained long-term. Severe persistent deficits, particularly ongoing recumbency risk or urinary dysfunction, may compromise quality of life to the point where humane euthanasia becomes appropriate. Individual circumstances guide these difficult decisions.

High-risk breeds for Equine Herpesvirus Myeloencephalopathy have not been clearly identified, as the condition can affect horses of any breed exposed to neuropathogenic EHV-1 strains. All horses carry equal susceptibility to infection, with individual factors including age and immune status influencing risk of developing neurological complications. No breed-specific genetic susceptibility has been documented. The widespread nature of EHV-1 infection means horses of all breeds in all geographic regions face potential exposure.

Use and discipline considerations affect EHM risk primarily through exposure patterns rather than inherent susceptibility. Horses that travel frequently to competitions, shows, and sales face increased exposure risk through contact with horses from diverse sources. Boarding facilities, training centers, and veterinary hospitals with high horse turnover present elevated transmission risk. Racing populations with frequent movement between tracks may experience outbreak situations. Breeding operations face particular concern due to the additional risk of EHV-1-induced abortion affecting pregnant mares.

Genetic testing and breeding recommendations for EHM do not apply as they would for hereditary conditions, since the disease results from viral infection rather than genetic susceptibility. However, breeding operations should implement biosecurity practices that protect pregnant mares from EHV-1 exposure given the abortion risk. Vaccination of broodmares according to recommended protocols provides partial protection. Selection of stallions and mares for breeding is not affected by EHM history, though horses actively infected should not be bred until fully recovered and no longer shedding virus.

Commonly co-occurring conditions with Equine Herpesvirus Myeloencephalopathy include respiratory disease caused by the same EHV-1 infection, which may precede or accompany neurological signs. Abortion in pregnant mares exposed to EHV-1 may occur simultaneously with neurological cases during outbreaks. Secondary complications in neurologically affected horses include aspiration pneumonia from swallowing dysfunction, urinary tract infections from bladder dysfunction, and pressure sores in recumbent horses. Laminitis may develop in horses with limited mobility or those receiving corticosteroid treatment.

Conditions with similar symptoms requiring differentiation from EHM include West Nile Virus encephalitis, which produces similar neurological signs including hindlimb weakness. Equine Protozoal Myeloencephalitis causes spinal cord disease with hindlimb predominance in some cases. Cervical vertebral malformation produces hindquarter ataxia though typically with more gradual onset. Equine Degenerative Myeloencephalopathy causes symmetrical ataxia in young horses. Spinal cord trauma and neoplasia affecting the spinal cord warrant consideration. The presence of fever and respiratory signs, combined with positive EHV-1 testing, helps distinguish EHM from these conditions.

Potential complications of Equine Herpesvirus Myeloencephalopathy extend beyond the immediate neurological injury. Permanent neurological deficits affect many survivors, limiting future use. Urinary complications including chronic bladder dysfunction and recurrent infections may persist. Myopathy from recumbency damages muscles in horses that go down. Corneal ulcers can develop in recumbent horses with reduced blink reflexes. Outbreak situations create stress and management challenges affecting entire facilities. Economic impacts include treatment costs, loss of affected horses, quarantine expenses, and event cancellations.